Business Context and Reporting Period
Company: Protagonist Therapeutics, Inc. (PTGX)
Filing Type: Form 8-K (Current Report)
Report Date: February 28, 2022
Reporting Period: Fourth Quarter and Full Year ended December 31, 2021
Context: The filing serves to announce the release of financial results and a corporate update for the specified period. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
Revenue, Profit, Cash Flow, Margins, Debt, and Liquidity: The provided 8-K text does not contain specific numerical values for revenue, net income, operating cash flow, margins, debt levels, or liquidity positions. These figures are referenced as being contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the text of this filing.
Material Changes
Comparison to Prior Period: The filing text does not provide specific data points or percentage changes comparing the current period to prior periods. It only confirms that results for the quarter and year ended December 31, 2021, have been reported.
Guidance, Outlook, and Risks
Management Commentary and Outlook: The filing references a press release titled "Protagonist Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update." Specific details regarding future guidance, strategic outlook, or management commentary are not present in the 8-K text itself.
Risks and Contingencies: No specific risks, contingencies, or unusual items are detailed in the body of this filing. The document includes a standard disclaimer that the information is not "filed" for purposes of Section 18 of the Exchange Act and shall not be incorporated by reference into other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (the press release) for specific financial figures including revenue, net loss, and cash position.
- Verify the "Corporate Update" section in the press release for details on clinical trial progress or pipeline milestones.
- Confirm the company's status as an emerging growth company and any associated election regarding extended transition periods for accounting standards.
- Check subsequent filings for any updates to the financial results announced on February 28, 2022.